Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24163448 | 0.86 | ALDH1A1 (0.74) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944749 | 0.85 | ALDH1A1 (0.76) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944758 | 0.85 | ALDH1A1 (0.76) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944746 | 0.85 | ALDH1A1 (0.76) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944530 | 0.83 | KDM4E (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944532 | 0.83 | KDM4E (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944523 | 0.82 | MEN1 (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL14748357 | 0.79 | KMT2A (0.52) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL16294450 | 0.78 | KMT2A (0.64) | KMT2AMEN1LCKDRD3 | |
| SCHEMBL20944694 | 0.78 | ALDH1A1 (0.52) | KMT2AKDM4EMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | KMT2A 967/4885KDM4E 1108/4885MEN1 4238/4885 |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | JAK2, JAK1, JAK3 | KMT2A 967/4885KDM4E 1108/4885MEN1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.